Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Applied Genetic Technologies Corp    AGTC

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Applied Genetic Technologies Corp (NASDAQ:AGTC) reported earnings of ($0.18) per share missing Walls Streets expectations.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2017 | 03:43pm CET

Applied Genetic Technologies Corp (NASDAQ:AGTC) reported Q4 2017 earnings this Morning, coming in at ($0.18) per share, missing Wall Street’s estimates of $0.14 per Share. Revenue for the quarter came in at $8.30 million beating analyst estimates of $12.39 million

Analyst Coverage For Applied Genetic Technologies Corp (NASDAQ:AGTC)
These are 3 Hold Ratings, 6 Buy Ratings .
The current consensus rating for Applied Genetic Technologies Corp (NASDAQ:AGTC) is Buy (Score: 2.67) with a consensus target price of $14.63 , a potential (195.45% upside)Recent Insider Trading for Applied Genetic Technologies Corp (NASDAQ:AGTC)

  • On 11/16/2016Ivana Magovcevic, Director, bought 3,000 with an average share price of $9.63 per share and the total transaction amounting to $28,890.00.
  • On 11/1/2016 Jeffrey D Chulay, VP, sold 1,000 with an average share price of $7.05 per share and the total transaction amounting to $7,050.00.
  • On 9/22/2016 Mark S Shearman, Insider, bought 3,000 with an average share price of $8.87 per share and the total transaction amounting to $26,610.00.
  • On 9/20/2016 Stephen W Potter, Insider, bought 1,400 with an average share price of $8.89 per share and the total transaction amounting to $12,446.00.
  • On 9/19/2016 Lawrence E Bullock, CFO, bought 10,000 with an average share price of $8.75 per share and the total transaction amounting to $87,500.00.
  • On 2/23/2015 Plc Glaxosmithkline, Major Shareholder, sold 503,150 with an average share price of $22.00 per share and the total transaction amounting to $11,069,300.00.

    Recent Trading for Applied Genetic Technologies Corp (NASDAQ:AGTC) Shares of Applied Genetic Technologies Corp closed the previous trading session at with shares trading hands.

    The post Applied Genetic Technologies Corp (NASDAQ:AGTC) reported earnings of ($0.18) per share missing Walls Streets expectations. appeared first on Market Exclusive.

    © Market Exclusive 2017, source Market Exclusive

    share with twitter share with LinkedIn share with facebook
    share via e-mail
    0
    Latest news on APPLIED GENETIC TECHNOLOGI
    01/22 APPLIED GENETIC TECHNOLOGIES : Equities Analysts Offer Predictions for Applied G..
    2017 APPLIED GENETIC TECHNOLOGIES CORP : Changes in Registrant's Certifying Accountan..
    2017 APPLIED GENETIC TECHNOLOGIES CORP : Change in Directors or Principal Officers (f..
    2017 AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthc..
    2017 APPLIED GENETIC TECHNOLOGIES : posts 1Q loss
    2017 APPLIED GENETIC TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL..
    2017 APPLIED GENETIC TECHNOLOGIES CORP : Results of Operations and Financial Conditio..
    2017 AGTC Announces Financial Results and Business Update for the Quarter Ended Se..
    2017 AGTC to Host First Quarter Financial Results Conference Call and Webcast on N..
    2017 AGTC and the Medical College of Wisconsin Announce Publication of Natural His..
    More news
    News from SeekingAlpha
    2017 After Hours Gainers / Losers
    2017 EDITORS' PICKS DAILY : Is Downsizing A Fad?
    2017 APPLIED GENETIC TECHNOLOGIES CORP. : A Forgotten Net-Net With Clear Upside Catal..
    2017 Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q1 2018 Results - Earn..
    2017 Applied Genetic beats by $0.01, beats on revenue
    Financials ($)
    Sales 2018 33,1 M
    EBIT 2018 -18,4 M
    Net income 2018 -17,6 M
    Debt 2018 -
    Yield 2018 -
    P/E ratio 2018 -
    P/E ratio 2019
    Capi. / Sales 2018 2,27x
    Capi. / Sales 2019 2,64x
    Capitalization 75,1 M
    Chart APPLIED GENETIC TECHNOLOGI
    Duration : Period :
    Applied Genetic Technologi Technical Analysis Chart | AGTC | US03820J1007 | 4-Traders
    Technical analysis trends APPLIED GENETIC TECHNOLOGI
    Short TermMid-TermLong Term
    TrendsBullishNeutralBearish
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus OUTPERFORM
    Number of Analysts 6
    Average target price 8,17 $
    Spread / Average Target 97%
    EPS Revisions
    Managers
    NameTitle
    Susan B. Washer President, Chief Executive Officer & Director
    William A. Sullivan Chief Financial Officer
    Mark S. Shearman Chief Scientific Officer & Vice President
    Matthew Feinsod Chief Medical Officer
    James Rosen Independent Director
    Sector and Competitors
    1st jan.Capitalization (M$)
    APPLIED GENETIC TECHNOLOGIES CORP13.89%75
    GILEAD SCIENCES13.04%106 315
    VERTEX PHARMACEUTICALS5.41%40 948
    REGENERON PHARMACEUTICALS-1.18%40 382
    GENMAB13.75%11 797
    BIOVERATIV INC18.90%11 230